Loading... Please wait...
Sort by:
  • NPS+ Asthma/COPD (EU5) 2017
    Learn More NPS+ Asthma/COPD (EU5) 2017
    Is there a loyalty issue for the leading asthma/COPD brands in Europe? With so many mono and combination therapies on offer to treat asthma and COPD, how is an abundance of choice impacting brand loyalty? What do...
  • NPS+ Asthma/COPD (US) 2017
    Learn More NPS+ Asthma/COPD (US) 2017
    Is there a loyalty issue for the leading asthma/COPD brands in the US?  With so many mono and combination therapies on offer to treat asthma and COPD, how is an abundance of choice impacting brand loyalty? What do...
  • Medical Affairs Reputations: HIV (EU5) 2017
    Learn More Medical Affairs Reputations: HIV (EU5) 2017
    Targeted improvements could help your medical affairs team win over doctors The infectious disease specialists we surveyed say medical affairs teams for 9 major HIV treatments could be doing a better job. They...
  • Medical Affairs Reputations: HIV (US) 2017
    Learn More Medical Affairs Reputations: HIV (US) 2017
    Survey shows medical affairs teams must be more active and provide better information Doctors say medical affairs teams for 10 major HIV treatments could be doing a better job. In the past 6 months, only one of those...
  • Real World Data: Meeting Payer Needs
    Learn More Real World Data: Meeting Payer Needs
    How to adjust your Real World Data provision to address the real needs of payers Drug costs are spiralling upwards and so too are frustration levels. Payers with stretched budgets are still struggling to make the case...
  • AML: KOL Insight: Update Bulletin [May 2017]
    Learn More AML: KOL Insight: Update Bulletin [May 2017]
    This update bulletin  presents key opinion leader (KOL) views on recent developments in the acute myeloid leukaemia (AML) market. Topics covered include: Novartis receiving US FDA approval for Rydapt (midostaurin)...
  • HNSCC: KOL Insight: Update Bulletin [May 2017]
    Learn More HNSCC: KOL Insight: Update Bulletin [May 2017]
    This edition presents key opinion leader (KOL) views on recent developments in the treatment of head and neck small cell carcinoma (HNSCC). Topics covered include: KOL views on the approval of Bristol Myers...
  • How Payers Want to Work With Pharma
    Learn More How Payers Want to Work With Pharma
    How to effectively engage US and EU payers You’re speaking to payers, but are they listening?  Do you really understand their needs and concerns?  Is your approach to payer negotiations getting your...
  • Medical Affairs in Orphan Drugs
    Learn More Medical Affairs in Orphan Drugs
    Orphan drugs: Is your medical affairs team leading the fray or lagging behind?  Traditional commercial models simply don’t work for orphan drugs, not least because the physician and patient populations are so...
  • Targeted Therapies in Asthma: KOL Insight: Update Bulletin [April 2017]
    Learn More Targeted Therapies in Asthma: KOL Insight: Update Bulletin [April 2017]
    This edition presents key opinion leader (KOL) views on recent developments in the targeted asthma treatment market. Topics covered include; GlaxoSmithKline’s (GSK) presentation of new data at the American Academy...
  • Multiple Sclerosis - Payer Insight: Update Bulletin [April 2017]
    Learn More Multiple Sclerosis - Payer Insight: Update Bulletin [April 2017]
    Topics covered in this update include: payers’ approaches to the reimbursement of Ocrevus (ocrelizumab; Roche/Biogen) for relapsing remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis...
  • Prostate Cancer: Update Bulletin [April 2017]
    Learn More Prostate Cancer: Update Bulletin [April 2017]
    Gain new key opinion leader (KOL) insights on the latest events happening in prostate cancer. Topics covered include expert opinions on the two oral PARP inhibitors (AstraZeneca’s Lynparza [olaparib] and Clovis...
  • Psoriasis: Update Bulletin [April 2017]
    Learn More Psoriasis: Update Bulletin [April 2017]
    This edition presents key opinion leader (KOL) views on recent developments in the moderate to severe psoriasis treatment market. Topics covered include: Janssen Biotech announcing new data from two pivotal Phase III...
  • Pulling the Data Puzzle Together: Being Payer-Centric
    Learn More Pulling the Data Puzzle Together: Being Payer-Centric
    Mapping data with payer needs. How to solve the data puzzle.  Everyone is talking about data. What’s being collected; how robust is it; what does it prove; who should be told? From the all-important payer...
  • Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2017
    Learn More Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2017
    Better information provision could give your medical affairs team a boost with doctors Is your medical affairs team giving doctors the information they need? Maybe not, according to our survey of 100 medical oncologists...
  • Medical Affairs Reputations: Renal Cell Carcinoma (US) 2017
    Learn More Medical Affairs Reputations: Renal Cell Carcinoma (US) 2017
    Better information provision could give your medical affairs team a boost with doctors Is your medical affairs team giving doctors the information they need? Maybe not, according to our survey of 100 medical oncologists...

customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved